Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience
J Haridy, A Wigg, K Muller, J Ramachandran, E Tilley, V Waddell, D Gordon, D Shaw, D Huynh, J Stewart, R Nelson, M Warner, M Boyd, MA Chinnaratha, D Harding, L Ralton, A Colman, D Liew, G Iyngkaran, E Tse
JOURNAL OF VIRAL HEPATITIS | WILEY | Published : 2018
In March 2016, the Australian government offered unrestricted access to direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) to the entire population. This included prescription by any medical practitioner in consultation with specialists until sufficient experience was attained. We sought to determine the outcomes and experience over the first twelve months for the entire state of South Australia. We performed a prospective, observational study following outcomes of all treatments associated with the state's four main tertiary centres. A total of 1909 subjects initiating DAA therapy were included, representing an estimated 90% of all treatments in the state. Overall, SV..View full abstract
JH is supported by an Australian Government Research Training Program Scholarship. JH has received speakers' payments from BMS and MSD, unrelated to this study. DL has received consulting fees and travel grants from AbbVie, unrelated to this study. AW has received speakers' payments from Gilead, AbbVie and MSD unrelated to this study. He has received consulting fees and travel grants from AbbVie, unrelated to this study. AW's department where he is employed has received grant support from AbbVie, MSD and Norgine, unrelated to this study. DG has received research funding support from Sanofi-Pasteur, unrelated to hepatitis C. MB has received research grants (paid to his institution) from Gilead and MSD. He has received honoraria for participation on HIV Advisory Boards and the preparation and presentation of educational materials from Gilead and ViiV Healthcare. GI has received research funding from BMS and MSD unrelated to this study. ET has received research funding from BMS and MSD, consultancy and speakers' payments from BMS, Gilead and MSD unrelated to this study.